Prescribing guide
Cuvrior (trientine tetrahydrochloride)Conversion from penicillamine, administration timing, copper monitoring and prior authorization for Wilson diseaseFor prescribers and their offices treating wilson disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS and no boxed warning; confirm stable, de-coppered Wilson disease tolerant to penicillamine, convert the penicillamine dose by Table 1, discontinue penicillamine before day 1, and send the Navigator Start Form or an eRx to PANTHERx Rare, the only dispensing pharmacy.
Example PA threshold
Cigna example, December 10, 2025: diagnosis by biallelic ATP7B variants or 2 of Kayser-Fleischer rings, ceruloplasmin under 20mg/dL, consistent liver biopsy and 24-hour urine copper over 40mcg; 1 of 6 reasons for trientine; GI, hepatology or transplant prescriber.
Monitoring
Serum non-ceruloplasmin copper at initiation, 3 months and about every 6 months; 24-hour urinary copper every 6 to 12 months as an option; watch for early clinical or neurological worsening, copper deficiency, iron deficiency and rash.
Support line
Navigator Program, 1-877-995-ORPH (6774), Start Form by fax 1-866-716-ORPH (6774), copay as little as $0 per fill for commercial plans with an annual cap, Quick Start of a free 30-day supply plus a one-month refill after a 5-day coverage delay, and a Patient Assistance Program.
Give your patient their plan
A one-page handout for starting Cuvrior, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/cuvriorBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Confirm the indication | Adults with stable Wilson disease who are de-coppered and tolerant to penicillamine. Pediatric safety and effectiveness are not established. Avoid in patients unable to swallow tablets. | FDA label |
| Convert the dose | Use Table 1 for the starting total daily dose from the penicillamine dose, 300mg to 3,000mg. Discontinue penicillamine before starting Cuvrior. For a switch from trientine hydrochloride, note 167mg base per 250mg capsule against 150mg per 300mg tablet. | FDA label |
| Baseline copper | Evaluate serum non-ceruloplasmin copper when initiating Cuvrior; the label adjusts the dose on clinical assessment and NCC. | FDA label |
| Send the Start Form | The Start Form serves as the prescription and enrolls the patient in the Navigator Program; fax 1-866-716-ORPH (6774) with front and back copies of all medical and pharmacy insurance cards. The patient signs the authorization section. | Start Form |
| Or send an eRx | To PANTHERx Rare Pharmacy, NPI 1316213531 or 1750843314, 1120 Stevenson Mill Road, Suite 400, Coraopolis, PA 15108. An eRx does not enroll the patient in the Navigator Program. | Prescribing Cuvrior |
| Quick Start attestation | Required for a free 30-day supply with 1 refill: diagnosed Wilson disease, age 18 or older, not treatment naive and de-coppered, and no prior Cuvrior. Eligibility requires insurance and a coverage delay of at least 5 days; patients may not re-enroll. | Start Form |
| Prior authorization | PANTHERx Rare starts an ePA through CoverMyMeds where available and faxes the office the key, or gathers the payer's forms for a manual PA. PANTHERx cannot submit the PA or write a letter of medical necessity; fax approvals and denials to 1-866-716-ORPH (6774). | Reimbursement Guide |
| Program resources | Orphalan offers prescribers a sample letter of medical necessity, a reimbursement guide and a dosing calculator on its HCP support page. | Navigator for prescribers |
Prior authorization criteria and what to document
One public policy as the example: Cigna, December 10, 2025. Approval a year at a time; the policy covers both Cuvrior and trientine hydrochloride capsules with the same criteria. This Cigna National Formulary policy was reviewed in December 2025 and cites the June 2025 Cuvrior label, so it postdates the current label. Its 6 reasons were written for trientine in general and do not name the Cuvrior label's own group, adults stable and tolerant on penicillamine. Other plans set their own criteria, and this one is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Biallelic pathogenic ATP7B variants, or at least 2 of Kayser-Fleischer rings, ceruloplasmin under 20mg/dL, a consistent liver biopsy and 24-hour urine copper over 40mcg | Genetic report, or the slit-lamp note and lab or pathology reports | Cigna policy |
| Reason for trientine | 1 of: penicillamine tried and not tolerated; features suggesting potential intolerance, such as renal disease, congestive splenomegaly with severe thrombocytopenia or an autoimmune tendency; a contraindication; neurologic manifestations; pregnancy; or already started on trientine | Prescriber's statement and chart notes | Cigna policy |
| Prescriber | Prescribed by or in consultation with a gastroenterologist, hepatologist or liver transplant physician | Specialty on the request, or the consult note | Cigna policy |
| Label population | The label indication is stable, de-coppered adults tolerant to penicillamine; the trial enrolled patients on penicillamine for at least 1 year with NCC from 25 to 150mcg/L | Penicillamine history, current dose and recent NCC; the policy's 6 reasons do not name this population | FDA label |
| Appeal | Orphalan's guide lists the denial letter, chart notes and a letter of medical necessity; external review requests are typically due within 60 days of the denial | Fax the appeal packet to PANTHERx Rare as well | Reimbursement Guide |
Cuvrior dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | Starting total daily dose from Table 1, 300mg to 3,000mg, in 2 divided doses; maximum 3,000mg a day. Table 2: 300mg is 1 tablet morning; 900mg is 2 morning and 1 evening; 1,800mg is 3 and 3; 3,000mg is 5 and 5. | FDA label |
| Each dose | Empty stomach, at least 1 hour before or 2 hours after meals and at least 1 hour apart from other food or milk. Swallow whole; a scored tablet may be halved. Remove from the blister only at dosing and do not store a removed tablet. | FDA label |
| Titration | Adjust on clinical assessment and serum NCC. In the trial, 3 of 26 patients increased and 1 reduced the dose over 24 weeks; the mean total daily dose was 1,800mg. | FDA label |
| Supply | 300mg tablets, 8 per child-resistant small carton, 9 small cartons and 72 tablets per large carton; the smallest dispensable unit is 8 tablets. Store at 20°C to 25°C (68°F to 77°F). | FDA label |
| Days' supply | The Start Form's Quick Start prescription is a 30-day supply with 1 refill; the ongoing prescription's quantity, days' supply and refills are written by the prescriber. | Start Form |
| Missed dose | The label gives no missed-dose instruction. | FDA label |
| Pregnancy | Monitor copper throughout pregnancy and use the minimum effective dose; the label notes untreated or discontinued treatment may worsen hepatic and neurological disease. | FDA label |
Monitoring the Cuvrior label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Initiation | Serum non-ceruloplasmin copper | Baseline for dose adjustment | FDA label |
| 3 months | Serum non-ceruloplasmin copper | Adjust the dose on NCC and clinical assessment | FDA label |
| About every 6 months | Serum non-ceruloplasmin copper; 24-hour urinary copper excretion every 6 to 12 months as an option | In the trial, mean UCE at week 36 was 274mcg/24h on Cuvrior against 511 on penicillamine; the label notes UCE falls on switching from penicillamine to trientine | FDA label |
| Early weeks | Clinical or neurological worsening from copper mobilization | Adjust the dosage or discontinue | FDA label |
| Any time | Copper deficiency, iron deficiency, rash or other hypersensitivity | Iron may be given in short courses 2 hours apart; consider discontinuing for rash, which occurred in 12% (3/26) with 1 discontinuation | FDA label |
| Trial context | NCC in the trial used an assay not commercially available | Week 36 mean NCC 56mcg/L on Cuvrior against 46 on penicillamine, difference -9 (95% CI -24 to 6); all patients were adjudicated clinically stable | FDA label |
| Trial record | CHELATE, NCT03539952, sponsored by Orphalan | Completed; primary completion August 19, 2020, results posted April 20, 2023 | ClinicalTrials.gov |
Cuvrior drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Mineral supplements | Avoid iron, zinc, calcium and magnesium; Cuvrior can chelate them and lose effect. If unavoidable, iron at least 2 hours before or after, other minerals at least 1 hour before or 2 hours after. | FDA label |
| Other oral drugs | At least 1 hour apart from any other oral drug | FDA label |
| Food and milk | At least 1 hour before or 2 hours after meals, and at least 1 hour apart from other food or milk | FDA label |
| Penicillamine | Discontinue before starting Cuvrior | FDA label |
| Other trientine | Not substitutable mg for mg; 167mg base per 250mg trientine hydrochloride capsule against 150mg per 300mg Cuvrior tablet | FDA label |
| Overdose | No antidote; a 60g trientine hydrochloride overdose caused nausea, vomiting, dizziness, mild acute kidney injury, mild hypophosphatemia and low copper and zinc; chronic overdosing has caused sideroblastic anemia | FDA label |
Why a first fill stalls, and the fix
- The prescription went to another pharmacyOrphalan says Cuvrior is available only through PANTHERx Rare Pharmacy. The prescriber's office resends the Start Form or an electronic prescription there. This is a routing problem for the office to fix, not an insurance denial.
- The Navigator offers never startedAn electronic prescription starts the insurance check but does not enroll you in the Navigator Program. The Start Form does both, and your signature on it lets the program check which offers fit you.
- Prior authorization pending or deniedCigna's policy, reviewed December 10, 2025, asks for a confirmed diagnosis, a liver or digestive specialist, and one of 6 reasons for trientine. If coverage is delayed at least 5 days, an eligible patient may get a free 30-day Quick Start supply.
- The plan's reasons do not fit a switchCigna's 6 reasons include penicillamine intolerance, neurologic symptoms, pregnancy and already taking trientine. The Cuvrior label's own group, stable adults who tolerate penicillamine, is not named among them.
- The appeal was deniedOrphalan's guide says an appeal includes the denial letter, chart notes and a letter of medical necessity. Once all appeals are used up, including an external review, a patient may qualify for free medicine through the Patient Assistance Program.
- A copay you cannot payEligible patients with commercial insurance may pay as little as $0 per fill, up to an annual cap Orphalan does not publish. Medicare, including Part D, Medicaid, TRICARE and VA coverage are excluded from the copay program.
Navigator Program by Orphalan
- A dedicated Care Coordinator who gives education and support about getting your medicine
- The Quick Start Program, a free 30-day supply plus a one-month refill for insured adults new to Cuvrior whose coverage has been delayed at least 5 days Start Form
- A copay program for commercial or private insurance, as little as $0 per fill up to an annual cap, not valid with Medicare, including Part D, Medicaid, TRICARE or VA Copay terms
- A Patient Assistance Program for people who are uninsured or underinsured, after enrollment and a financial assessment
- Delivery from PANTHERx Rare Pharmacy, the only pharmacy that dispenses Cuvrior Prescribing Cuvrior
Questions prescribers' offices ask about Cuvrior
How is penicillamine converted to Cuvrior?
Per Table 1 of the current label (highlights revised 1/2024, DailyMed version June 19, 2025), penicillamine 125mg, 250mg, 375mg, 500mg, 625mg, 750mg, 875mg, 1,000mg, 1,125mg, 1,250mg, 1,375mg and 1,500mg or more map to Cuvrior 300mg, 600mg, 900mg, 900mg, 1,200mg, 1,500mg, 1,800mg, 2,100mg, 2,400mg, 2,400mg, 2,700mg and 3,000mg a day. Discontinue penicillamine before starting, divide the total into 2 doses with the larger number of tablets in the morning, and do not exceed 3,000mg a day.
How does Cuvrior compare with trientine hydrochloride by dose?
Not substitutable mg for mg, per section 2.3 of the current label (revised 1/2024): a 250mg trientine hydrochloride capsule contains 167mg trientine base and a 300mg Cuvrior tablet contains 150mg. In healthy subjects, 900mg Cuvrior gave an 11% lower mean AUC than 750mg trientine hydrochloride, and 1,500mg Cuvrior was comparable to 1,250mg. Orphalan states there is no standard conversion from zinc.
What monitoring does the Cuvrior label require?
Serum non-ceruloplasmin copper at initiation, at 3 months and about every 6 months thereafter, per section 2.4 of the current label (revised 1/2024), with 24-hour urinary copper excretion every 6 to 12 months as an option. Monitor for copper deficiency, especially in pregnancy, and for iron deficiency; adjust or discontinue if the clinical condition worsens at initiation.
What are the Cuvrior administration rules?
Per section 2.2 of the current label (revised 1/2024), give it on an empty stomach at least 1 hour before or 2 hours after meals and at least 1 hour apart from other food, milk or oral drugs. Avoid mineral supplements; if unavoidable, separate iron by at least 2 hours either side and other minerals by at least 1 hour before or 2 hours after.
What do insurers ask for to approve Cuvrior?
The Cigna National Formulary policy reviewed December 10, 2025 asks for a confirmed diagnosis, 1 of 6 reasons for trientine and a gastroenterologist, hepatologist or liver transplant physician, with approval for 1 year. Its 6 reasons do not include the label's population of stable patients tolerant to penicillamine; already started on trientine is one of them.
Free email alert
Get an email when the Cuvrior label changes
One email the day the FDA revises the Cuvrior prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Cuvrior only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- CUVRIOR- trientine tetrahydrochloride tablet, film coated, prescribing information, highlights revised 1/2024, DailyMed version 7, Orphalan SA, via DailyMed, 2025-06-19.
- CUVRIOR (trientine tetrahydrochloride) tablets, for oral use, prescribing information, Revised 4/2022, FDA, Drugs@FDA, 2022-04-28.
- NDA 215760 approval letter, Cuvrior (trientine tetrahydrochloride) tablets, FDA, 2022-04-28.
- Navigator Program: Patient Support by Orphalan, Orphalan, 2026-11-09.
- Navigator Program: Patient Support by Orphalan, Patient Support and Resources for healthcare professionals, Orphalan, 2026-11-09.
- Prescribing CUVRIOR, Orphalan, 2026-11-09.
- Navigator Program Start Form, US-ORPH-CUVR-25005, June 2025, Orphalan, 2026-11-09.
- Navigator Program Terms & Conditions, Orphalan, 2026-11-09.
- Navigator Program Reimbursement Guide, US-ORPH-CUVR-24060, July 2024, Orphalan, 2026-11-09.
- Chelating Agents, Trientine Products Prior Authorization Policy, Cigna National Formulary Coverage, Cigna, 2025-12-10.
- CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease, NCT03539952, ClinicalTrials.gov, record updated July 2, 2025, 2025-07-02.
A reference drawn from the June 19, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 9, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.